Published in Med Microbiol Immunol on June 04, 2009
The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog (2013) 1.18
Vaccination against infectious diseases: what is promising? Med Microbiol Immunol (2014) 1.03
An RNA replication-center assay for high content image-based quantifications of human rhinovirus and coxsackievirus infections. Virol J (2010) 0.93
Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul. Med Microbiol Immunol (2013) 0.93
Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients. Med Microbiol Immunol (2010) 0.88
Therapeutic vaccination in chronic hepatitis B--approaches, problems, and new perspectives. Preface. Med Microbiol Immunol (2015) 0.87
Do fewer cases of Kaposi's sarcoma in HIV-infected patients reflect a decrease in HHV8 seroprevalence? Med Microbiol Immunol (2011) 0.86
Human immunodeficiency virus type-1 group M quasispecies evolution: diversity and divergence in patients co-infected with active tuberculosis. Med Microbiol Immunol (2010) 0.82
Recent publications in medical microbiology and immunology: a retrospective. Med Microbiol Immunol (2011) 0.81
HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany. Med Microbiol Immunol (2011) 0.78
Regional spread of HIV-1 M subtype B in middle-aged patients by random env-C2V4 region sequencing. Med Microbiol Immunol (2010) 0.78
Replacement of biologic by molecular techniques in diagnostic virology: thirty years after the advent of PCR technology-do we still need conventional methods? Med Microbiol Immunol (2013) 0.77
The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes. Med Microbiol Immunol (2011) 0.77
Escherichia coli-expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen. BMC Infect Dis (2012) 0.75
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med (1981) 14.62
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006) 5.31
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature (2008) 5.05
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Human immunodeficiency viruses: SIV infection in wild gorillas. Nature (2006) 3.35
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol (1999) 2.41
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (2007) 2.37
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology (2007) 2.01
Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol (2008) 1.97
Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol (2008) 1.85
The design of drugs for HIV and HCV. Nat Rev Drug Discov (2007) 1.85
Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis (2008) 1.81
Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther (2008) 1.63
Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol (2003) 1.61
Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS (2000) 1.61
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother (2007) 1.59
Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol (2003) 1.49
New therapies for hepatitis C virus infection. Clin Infect Dis (2009) 1.46
Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother (2009) 1.39
Simian immunodeficiency virus infection in wild-caught chimpanzees from cameroon. J Virol (2005) 1.36
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol (2009) 1.33
The history of cytomegalovirus and its diseases. Med Microbiol Immunol (2007) 1.32
Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol (2007) 1.28
HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS (2008) 1.24
HIV-1 resistance genotyping on dried serum spots. AIDS (2005) 1.23
An AIDS-like condition induced in baboons by HIV-2. Science (1994) 1.22
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2008) 1.16
The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab (2007) 1.10
Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol (2001) 1.06
Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis (2008) 1.03
Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill (2005) 1.01
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2008) 0.99
Antileishmanial activity of HIV protease inhibitors. Int J Antimicrob Agents (2005) 0.98
Infections among pygmies in the Eastern Province of Cameroon. Med Microbiol Immunol (1993) 0.97
AIDS: prehistory of HIV-1. Nature (2008) 0.92
Efficient replication of HTLV-III and STLV-IIImac in human Jurkat cells. Med Microbiol Immunol (1987) 0.86
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob Agents Chemother (2008) 0.84
Effect of HTLV-III on the macromolecular synthesis in HTLV-I carrying cell line, MT-4. Med Microbiol Immunol (1986) 0.83
Sequence diversity among chimpanzee simian immunodeficiency viruses (SIVcpz) suggests that SIVcpzPts was derived from SIVcpzPtt through additional recombination events. AIDS Res Hum Retroviruses (2007) 0.81
Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy. Virus Genes (2007) 0.81
The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med Microbiol Immunol (2006) 0.81
Seroepidemiology of human immunodeficiency viruses in Africa. Biomed Pharmacother (1988) 0.80
Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab (2008) 0.79
The threat of avian influenza A (H5N1). Part III: Antiviral therapy. Med Microbiol Immunol (2007) 0.79
Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing. J Virol Methods (1999) 0.77
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol (2003) 4.66
Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain. Clin Chem (2006) 2.32
Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol (2009) 1.65
Phylogeny of the SARS coronavirus. Science (2003) 1.56
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis (2013) 1.49
Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity. J Clin Microbiol (2002) 1.44
Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra. J Clin Microbiol (2002) 1.42
[When viruses jump over species boundaries. Are dogs and cats to be permitted into bed?]. MMW Fortschr Med (2003) 1.41
Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol (2003) 1.39
Confirmation of putative HIV-1 group P in Cameroon. J Virol (2010) 1.36
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med (2006) 1.34
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res (2009) 1.34
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett (2007) 1.20
Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol Med (2003) 1.13
Valproic acid as anti-cancer drug. Curr Pharm Des (2007) 1.11
Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chemother (2007) 1.11
Molecular mechanisms of the modulatory effects of HCMV infection in tumor cell biology. Trends Mol Med (2004) 1.11
Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol (2007) 1.10
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol (2009) 1.09
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol (2005) 1.08
SARS molecular detection external quality assurance. Emerg Infect Dis (2004) 1.08
Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One (2011) 1.06
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis (2002) 1.05
Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol (2004) 1.03
Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Med Microbiol Immunol (2009) 1.03
First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion (2009) 1.02
Rates of postoperative complications among human immunodeficiency virus-infected women who have undergone obstetric and gynecologic surgical procedures. Clin Infect Dis (2002) 1.01
Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res (2003) 0.99
Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev Mol Diagn (2007) 0.98
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia (2010) 0.97
Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther (2003) 0.96
Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology (2007) 0.95
Novel approach for genotyping varicella-zoster virus strains from Germany. J Clin Microbiol (2007) 0.95
Infection of human retinal pigment epithelial cells with influenza A viruses. Invest Ophthalmol Vis Sci (2009) 0.94
West Nile virus infection induces interferon signalling in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2006) 0.93
Construction and characterization of an HIV-1 group O infectious molecular clone and analysis of vpr- and nef-negative derivatives. Virology (2004) 0.93
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol (2006) 0.93
NK sensitivity of neuroblastoma cells determined by a highly sensitive coupled luminescent method. Biochem Biophys Res Commun (2005) 0.92
Oncomodulation by human cytomegalovirus: evidence becomes stronger. Med Microbiol Immunol (2009) 0.92
Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia (2004) 0.92
Oncomodulation by human cytomegalovirus: novel clinical findings open new roads. Med Microbiol Immunol (2010) 0.91
Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia (2005) 0.91
Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol (2003) 0.91
Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systems. J Clin Virol (2002) 0.91
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun (2004) 0.90
Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition. Invest Ophthalmol Vis Sci (2005) 0.90
The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sci (2010) 0.90
Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sex Transm Dis (2010) 0.89
HBV reactivation after kidney transplantation. J Clin Virol (2005) 0.89
Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. Neoplasia (2008) 0.89
A novel internally controlled real-time reverse transcription-PCR assay for HIV-1 RNA targeting the pol integrase genomic region. J Virol Methods (2007) 0.88
Novel varicella-zoster virus glycoprotein E gene mutations associated with genotypes A and D. J Clin Microbiol (2007) 0.88
Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS One (2012) 0.87
Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. J Med Chem (2006) 0.87
Malaria. Transfus Med Hemother (2008) 0.86
Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine (2010) 0.86
Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. Med Microbiol Immunol (2009) 0.86
Role of tumor cell immune escape mechanisms in cytomegalovirus-mediated oncomodulation. Med Res Rev (2005) 0.86
Role of interferons in the treatment of severe acute respiratory syndrome. Expert Opin Biol Ther (2004) 0.86
Hepatitis E Virus. Transfus Med Hemother (2008) 0.86
Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid. Biochem Pharmacol (2004) 0.85
Influenza Virus. Transfus Med Hemother (2007) 0.85
Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res (2005) 0.85
Evaluation of the new ARCHITECT anti-HCV screening test under routine laboratory conditions. J Clin Virol (2008) 0.84
Problems and challenges in the diagnosis of vertical infection with human cytomegalovirus (CMV): lessons from two accidental cases. J Clin Virol (2011) 0.84
Impact of persistent cytomegalovirus infection on human neuroblastoma cell gene expression. Biochem Biophys Res Commun (2005) 0.84
Of chickens and men: avian influenza in humans. Curr Mol Med (2009) 0.84
Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica (2013) 0.84
Detection and quantitation of HBV DNA in miniaturized samples: multi centre study to evaluate the performance of the COBAS ® AmpliPrep/COBAS ® TaqMan ® hepatitis B virus (HBV) test v2.0 by the use of plasma or serum specimens. J Virol Methods (2010) 0.84
In vitro replication of varicella-zoster virus in human retinal pigment epithelial cells. J Clin Microbiol (2008) 0.83
A novel immunomodulatory mechanism of ribavirin in suppressing natural killer cell function. Biochem Pharmacol (2009) 0.83
[Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics]. Med Klin (Munich) (2010) 0.83
Human Cytomegalovirus (HCMV) - Revised. Transfus Med Hemother (2010) 0.83
Near full-length genome characterization of an HIV type 1 CRF25_cpx strain from Cameroon. AIDS Res Hum Retroviruses (2008) 0.83
A 10-year molecular survey of herpes simplex virus type 1 in Germany demonstrates a stable and high prevalence of genotypes A and B. J Clin Virol (2009) 0.82
High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells. Int J Mol Med (2005) 0.82
The human eye (retina): a site of persistent HCMV infection? Graefes Arch Clin Exp Ophthalmol (2005) 0.81
West nile virus. Transfus Med Hemother (2013) 0.81
Validation of the 'Marburg bone bank system' for thermodisinfection of allogenic femoral head transplants using selected bacteria, fungi, and spores. Biologicals (2003) 0.81
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antivir Ther (2007) 0.81
Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion. FASEB J (2006) 0.81
Novel approach to differentiate subclades of varicella-zoster virus genotypes E1 and E2 in Germany. Virus Res (2009) 0.81
HIV types, groups, subtypes and recombinant forms: errors in replication, selection pressure and quasispecies. Intervirology (2012) 0.80
Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation. J Clin Virol (2005) 0.80
Near full-length genome characterization of three additional HIV type 1 CRF13_cpx strains from Cameroon. AIDS Res Hum Retroviruses (2007) 0.80
3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. Biochem Pharmacol (2002) 0.80
Effects of S-acetylglutathione in cell and animal model of herpes simplex virus type 1 infection. Med Microbiol Immunol (2003) 0.80
Thrombin stimulates IL-6 and IL-8 expression in cytomegalovirus-infected human retinal pigment epithelial cells. Int J Mol Med (2004) 0.80
Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells. Cardiovasc Res (2007) 0.79
Dengue in travellers is still underestimated. Intervirology (2008) 0.79
The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β. Biochem Pharmacol (2010) 0.79
Orthopox Viruses: Infections in Humans. Transfus Med Hemother (2010) 0.79
Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species. Chem Biodivers (2008) 0.78
Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes. Antimicrob Agents Chemother (2011) 0.78
[Viral gastroenteritis. An epidemiologic investigation between the period 2001-2006]. Med Klin (Munich) (2008) 0.78
Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced pro-inflammatory cytokine and chemokine expression in human macrophages. Med Microbiol Immunol (2010) 0.78